title: Persistence of autonomous ovarian activity after discontinuation of therapy for precocious puberty in McCune-Albright syndrome.
abstract: OBJECTIVE
  The aim of this study was to evaluate the possibility of persistence of autonomous ovarian activity in girls with McCune-Albright syndrome (MAS) after withdrawal of medroxyprogesterone therapy administered for precocious puberty.
  
  
  METHODS
  Five girls with MAS were followed-up 1.2 to 8.5 years after the end of treatment. The girls underwent luteinizing hormone-releasing hormone (LH-RH) tests, estradiol (E2) basal measurement, and pelvic ultrasound two times in the follow-up period.
  
  
  RESULTS
  Menses resumed in four of five girls, 1.4 +/- 0.9 years after the end of treatment, at chronologic age of 11.3 +/- 1.3 years. Cycles for all girls were irregular. Three patients presented inadequate E2 levels (from 56 to 320 pg/mL) associated with low or absent gonadotropin response to LH-RH tests. The pelvic ultrasound showed ovarian cysts at the time of the study.
  
  
  CONCLUSIONS
  These hormonal and ultrasonographic findings provide evidence of persistence of autonomous ovarian activity in some young women with MAS.
authors.affiliation: Centro de Investigaciones Endocrinológicas, Hospital de Niños Dr. Ricardo Gutiérrez, Buenos Aires, Argentina.
authors.forename: M E
authors.initials: ME
authors.lastname: Escobar
authors.forename: M
authors.initials: M
authors.lastname: Gryngarten
authors.forename: H
authors.initials: H
authors.lastname: Domené
authors.forename: G
authors.initials: G
authors.lastname: Ropelato
authors.forename: M R
authors.initials: MR
authors.lastname: López
authors.forename: C
authors.initials: C
authors.lastname: Bergadá
mesh_terms: D002648:Child; D004958:Estradiol / Q000097:blood; D005260:Female; D005359:Fibrous Dysplasia, Polyostotic / Q000097:blood / Q000150:complications / Q000503:physiopathology*; D005640:Follicle Stimulating Hormone / Q000097:blood; D005500:Follow-Up Studies; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008525:Medroxyprogesterone / Q000627:therapeutic use*; D010053:Ovary / Q000000981:diagnostic imaging / Q000503:physiopathology*; D045167:Progesterone Congeners / Q000627:therapeutic use*; D011629:Puberty, Precocious / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology*; D014463:Ultrasonography
chemical_list: D045167:Progesterone Congeners; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D008525:Medroxyprogesterone